Most Read Articles
18 Jun 2019
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
6 days ago
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
Yesterday
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.

Quality of life, mental health poorer in patients with rare cancers

11 Oct 2018
Cancer is hard enough as it is – unnecessarily increasing the treatment does not help patients, doctors or the practice of healthcare in general.

Patients with rare cancers have worse psychosocial and quality of life outcomes compared with the general population of cancer patients, a recent study has shown.

Using the Distress Thermometer (DT), Hospital Anxiety and Depression Scale (HADS), and Functional Assessment of Cancer Therapy-General version, researchers assessed the mental health status and quality of life in 137 patients (mean age 50 years; 52.6 percent male) diagnosed with rare cancers. Chi-square tests were used to compare the rare vs general cancer populations.

In the study population, the most frequent form of rare cancer was seminoma of the testis, reported in 10.3 percent (n=14) of the participants. This was followed by endometroid adenocarcinoma (7.3 percent) and gastrointestinal stromal sarcoma (5.8 percent). Majority of the participants had received chemotherapy (73.7 percent) and surgery (76.6 percent).

According to the DT scale, almost half (49.6 percent) of the participants had moderate-to-severe distress, which was significantly higher than that in a US-based pan-cancer population (p=0.006). Physical (92.7 percent) and emotional (73.7 percent) problems were the principal drivers of distress.

Results of the HADS showed that the prevalence rates of anxiety and depressive symptoms were 19.7 percent and 15.3 percent, respectively, both of which were nonsignficantly lower than those in the pan-cancer cohort (24.0 percent and 15.3 percent, respectively).

Multivariate analysis identified various risk factors. Younger age was associated with significantly higher levels of distress (p=0.02), as were female sex (p<0.01) and undergoing evaluation during the active treatment phase (p=0.03). Female sex (p=0.0002) and being younger (p=0.04) were associated with greater anxiety.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
18 Jun 2019
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
6 days ago
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
Yesterday
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.